The options paper proposed creating a "unified, national" evaluation pathway for all health technologies. This would profoundly change decision-making and entrench significant additional power in Australia's HTA institution. …
Start planning for a change that would further entrench decision-making power
July 29, 2024 Latest NewsBioPharma
Latest Video
Georgia Forrest
New Stories
-
AusBiotech urges adoption national life sciences strategy as global competition intensifies
February 2, 2026 - - Australian Biotech -
Cyclopharm delivers record revenue as US emerges as growth engine
February 2, 2026 - - Australian Biotech -
Sandoz adds to vision care options with the listing of biosimilar aflibercept
February 2, 2026 - - Latest News -
PYC’s capital raise marks one of the largest biotech fundraisings in Australian market history
February 2, 2026 - - Australian Biotech -
Genetic Signatures appoints seasoned life sciences executive as CEO
February 2, 2026 - - Australian Biotech -
EMA decision clears regulatory path for Argenica’s lead stroke drug in Europe
February 2, 2026 - - Australian Biotech -
Recce Pharmaceuticals deepens US partnership to advance burn wound treatment
February 2, 2026 - - Australian Biotech